Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Fernández, Oscar ^a   Agüera, Javier ^b   Izquierdo, Guillermo ^c   Millán Pascual, Javier ^d   Ramió i Torrentà, Lluis ^e   Oliva, Pedro ^f   Argente, Javier ^g   Berdei, Yasmina ^h   Soler, Jose Maria ⁱ   Carmona, Olga ^j   Errea, Jose Maria ^k   Farrés, Jordi ^l  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f HUC de Asturias   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ Sant Joan de Déu Manresa Hospital   (Spain)

^j HOSPITAL DE FIGUERES   (Spain)

^k HOSPITAL DE BARBASTRO   (Spain)

^l Bayer Hispania   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ADULT; AGE; ARTICLE; COGNITION; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE DURATION; DOSE PERCENTAGE RECEIVED; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INFECTION; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MORISKY GREEN TEST; MULTIPLE SCLEROSIS; MYALGIA; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; QUESTIONNAIRE; RETROSPECTIVE STUDY; SELF INJECTION; SHIVERING; SPAIN; TREATMENT DURATION;

EID: 84872096979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035600     Document Type: Article

References (35)

1. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, et al. (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13 (7): 700-22.
2. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, et al. (1989) The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 112: 133-46.
3. Applebee A, Panitch H, (2009) Early stage and long term treatment of multiple sclerosis with interferon-beta. Biologics 3: 257-71.
4. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter,randomized, double-blind, placebo-controlled trial. Neurology 43: 655-61.
5. European Study Group on Interferon β-1b in Secondary Progressive MS (1998) Placebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-97.
6. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3 year follow-up analysis of the BENEFIT study. Lancet 370: 389-97.
7. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta 1-a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39: 285-294.
8. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, et al. (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59: 679-87.
9. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomized double-blind placebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-504.
10. PRISMS Study Group (2001) University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56: 1628-36.
11. (2001) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 56: 1505-13.
12. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, et al. (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503-11.
13. Wiendl H, Toyka KV, Rieckmann P, Gold R, et al. (2008) Multiple Sclerosis Therapy Consensus Group (MSTCG), Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255 (10): 1449-63.
14. World Health Organization (2003) Adherence to long-term therapies. Evidence for action World Health Organization.
15. Ruggieri MN, Settipani N, Viviano L, Attanasio M, Giglia L, et al. (2003) Long term interferon-beta treatment for multiple sclerosis. Neurol Sci 24: 361-364.
16. Haas J, Firzlaff M, (2005) Twenty-four-months comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol 12: 425-31.
17. Milanese L, La Mantia L, Palumbo R, Martinelli V, Murialdo A, et al. (2003) A post-marketing study on interferon beta-1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74: 1689-92.
18. Tremlett HL, Oger J, (2003) Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 61 (4): 551-4.
19. Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, et al. (2005) Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11 (3): 306-9.
20. Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, et al. (2008) Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 17 (6): 565-76.
21. Cunningham A, Gottberg K, von Koch L, Hillert J, (2010) Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta Neurol Scand 121 (3): 154-60.
22. Reynolds MW, Stephen R, Seaman C, Rajagopalan K, (2010) Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 26 (3): 663-74.
23. Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L, (2007) Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 259 (1-2): 104-8.
24. Patti F, (2010) Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 4: 1-9.
25. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, et al. (2011) The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 18 (1): 69-77.
26. Morisky DE, Green LW, Levine DM, (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24: 67-73.
27. García Pérez AM, Leiva Fernández F, Martos Crespo F, García Ruíz AJ, Prados Torres D, et al. (2000) ¿Cómo diagnosticar el cumplimiento terapéutico en atención primaria?. Medicina de Familia 1: 13-19.
28. Kurtzke JF, (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (Cleveland) 33: 1444-52.
29. Osterberg L, Blaschke T, (2005) Adherence to medication. N Engl J Med 2005; 353 (5): 487-97.
30. Steiner JF, Prochazka AV, (1997) The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 50 (1): 105-16.
31. Lau HS, de Boer A, Beuning KS, Porsius A, (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50 (5): 619-25.
32. Goldman Consensus Group (2005) Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis 11: 328-37.
33. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, et al. (1997) Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 54 (5): 531-3.
34. Adherence to self-injectable therapy in MS (2008) Neura: Perspectives in CNS disease management; 8 (3): 7-14.
35. Mohr DC, Goodkin DE, Likosky W, Gatto N, Neilley LK, et al. (1996) Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 2 (5): 222-6.